> > Congenital Factor VII Deficiency

Congenital factor VII deficiency.

NovoSeven® RT is the only factor product approved for congenital factor VII deficiency (CFVIId).1

> > Congenital Factor VII Deficiency

Congenital factor VII deficiency.

NovoSeven® RT is the only factor product approved for congenital factor VII deficiency (CFVIId).1

Why Novoseven RT?

Efficacy

Tailored dosing

Safety profile

Rapid reconstitution

Tab Efficacy

Offering the proven efficacy they expect.

NovoSeven® RT was 93% effective at stopping nonsurgical and surgical bleeds in people with CFVIId.1,2,a  

aData from the published literature and internal sources for patients with FVII deficiency (N=75) treated with NovoSeven® for 124 bleeding episodes, surgeries, or prophylaxis regimens. Dosing ranged from 6 mcg/kg administered every 2 to 12 hours (except for prophylaxis [doses administered from 2 times per day up to 2 times per week]). Patients were treated with an average of 1 to 10 doses. Treatment was effective if bleeding stopped or the physician rated the treatment as effective.1,2  
 

Tab Tailored Dosing

Adjustable dosing.

Based on the severity of bleeding, adjust dose and frequency of injections to each individual patient.

bThe minimum effective dose has not been determined.

Dosing recommendation for CFVIId.1,b

CONGENITAL FACTOR VII DEFICIENCY

15-30 mcg/kg

every 4-6 hours

until hemostasis is achieved

Effective treatment has been achieved with doses as low as 10 mcg per kg body weight.

Calculate a Dose for Your Patient

See perioperative dosing recommendations


bThe minimum effective dose has not been determined.
 

Tab Safety Profile

The safety they deserve.

NovoSeven® RT is the only recombinant bypassing agent not made from human serum or proteins. Recombinant manufacturing minimizes the possibility of viral contamination.1,3

Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance.1

See Important Safety Information.

Learn More About Recombinant Safety

Tab 3-step reconstitution

The rapid access to treatment that keeps them on the go.

NovoSeven® RT is room temperature stable up to 77°F.1,c

cPrior to reconstitution, store NovoSeven® RT powder and histidine diluent between 36–77°F. After reconstitution, store NovoSeven® RT either at room temperature or refrigerated for up to 3 hours. Do not freeze reconstituted NovoSeven® RT or store in syringes.

Thermometer displaying 77˚F

Quick reconstitution can save them time.

Every vial comes with a prefilled syringe, meaning no extra steps to fill a syringe with diluent.1,d  

See How MixPro® Works


dCompared with reconstitution using histidine vials.

Doctor attending to girl in hospital bed

Approved for surgical use and

procedures in patients with

congenital hemophilia FVII deficiency.

See more about surgical use

Chart icon

Looking for codes for

coagulation disorders?

Get the diagnosis codes

Girl carrying yoga mat

Hear what real patients say

about their experience.

Watch patient testimonial videos

Available from Novo Nordisk:

Novoeight® logo

Visit website | Prescribing Information

Rebinyn® logo

Visit website | Prescribing Information

Tretten® logo

Visit website | Prescribing Information

Selected Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Indications and Usage

NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
  • Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII

Please click here for Prescribing Information

References:

  1. NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2019.

  2. Mariani G, Napolitano M, Dolce A, et al. Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation. Thromb Haemost 2013; 109: 238–247.

  3. National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders, #250. New York, NY: National Hemophilia Foundation; 2017.